Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Homologous recombination in cancer development, treatment and development of drug resistance

29 Mar 2010

Abstract excerpt

Although DNA double-strand breaks (DSBs) are substrates for homologous recombination (HR) repair, it is becoming apparent that DNA lesions produced at replication forks, for instance by many anticancer drugs, are more significant substrates for HR repair. Cells defective in HR are hypersensitive to a wide variety of anticancer drugs, including those that do not produce DSBs. Several cancers have mutations in or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy
Share to Polyomavirus and related diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20351092
DOI: 10.1093/carcin/bgq064

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Homologous recombination in cancer development, treatment and development of drug resistancePMID 20351092Read ↗

Therapeutic targeting and patient selection for cancers with homologous recombination defects.Semantic proximity Read ↗

Exploiting the homologous recombination DNA repair network for targeted cancer therapySemantic proximity Read ↗

Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies.Semantic proximity Read ↗

Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapySemantic proximity Read ↗

Mechanism and significance of chromosome damage repair by homologous recombinationSemantic proximity Read ↗

DNA double-strand break repair pathway choice - from basic biology to clinical exploitationSemantic proximity Read ↗

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancersSemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP InhibitorsSemantic proximity Read ↗

Clinical relevance of the homologous recombination machinery in cancer therapySemantic proximity Read ↗

Homologous recombination repair deficiency (HRD): From biology to clinical exploitationSemantic proximity Read ↗

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.Semantic proximity Read ↗

Biomarkers for Homologous Recombination Deficiency in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.